|
ABBV
|
AbbVie Inc.
|
US
|
NYSE
|
|
ACOR
|
Acorda Therapeutics, Inc.
|
US
|
NASDAQ
|
|
ADTX
|
ADiTx Therapeutics, Inc.
|
US
|
NASDAQ
|
|
ALDX
|
Aldeyra Therapeutics, Inc.
|
US
|
NASDAQ
|
|
AMPE
|
Ampio Pharmaceuticals, Inc.
|
US
|
AMEX
|
|
ARGX
|
argenx SE
|
US
|
NASDAQ
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
US
|
NASDAQ
|
|
AUPH
|
Aurinia Pharmaceuticals Inc
|
US
|
NASDAQ
|
|
BLRX
|
BioLineRx Ltd.
|
US
|
NASDAQ
|
|
BMRN
|
BioMarin Pharmaceutical Inc.
|
US
|
NASDAQ
|
|
CABA
|
Cabaletta Bio, Inc.
|
US
|
NASDAQ
|
|
CASI
|
CASI Pharmaceuticals, Inc.
|
US
|
NASDAQ
|
|
CCXI
|
ChemoCentryx, Inc.
|
US
|
NASDAQ
|
|
CGEN
|
Compugen Ltd.
|
US
|
NASDAQ
|
|
ENZ
|
Enzo Biochem, Inc.
|
US
|
NYSE
|
|
FBIO
|
Fortress Biotech, Inc.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
FNCH
|
Finch Therapeutics Group, Inc.
|
US
|
NASDAQ
|
|
FWP
|
Forward Pharma A/S
|
US
|
NASDAQ
|
|
GLPG
|
Galapagos NV
|
US
|
NASDAQ
|